ANANDA PHARMA LIMITED

• ⚠

  Material uncertainty over going concern

  For the year ended 31 January 2025, the Group recorded a loss after tax of £3,770,487 and had net cash outflows, from operating activities of £816,385. Upon review of the cashflow forecast prepared through to 31 January 2027, an operating loss is expected in the year subsequent to the date of these accounts. The ability of the entity to continue as a going concern is dependent on the Group generating positive operating cash flows and/or securing additional funding through the raising of debt or equity to fund its projects. These conditions indicate a material uncertainty that may cast a significant doubt about the entity's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business.

1. ANANDA PHARMA LIMITED 2026-01-08 → present
2. ANANDA PHARMA PLC 2024-12-19 → 2026-01-08
3. ANANDA DEVELOPMENTS PLC 2018-05-04 → 2024-12-19
4. LONGDOG INVESTMENTS PLC 2018-01-19 → 2018-05-04

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

PKF Littlejohn LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“For the year ended 31 January 2025, the Group recorded a loss after tax of £3,770,487 and had net cash outflows, from operating activities of £816,385. Upon review of the cashflow forecast prepared through to 31 January 2027, an operating loss is expected in the year subsequent to the date of these accounts. The ability of the entity to continue as a going concern is dependent on the Group generating positive operating cash flows and/or securing additional funding through the raising of debt or equity to fund its projects. These conditions indicate a material uncertainty that may cast a significant doubt about the entity's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business.”

Group structure

1. ANANDA PHARMA LIMITED · parent
   1. DJT Plants Limited 100% · UK · Supporting activities crop production
   2. DJT Group Ltd 100% · UK · Growing of vegetables and melons, roots and tubers
   3. Tiamat Agriculture Ltd 100% · UK · Wholesale of pharmaceutical goods
   4. MRX Global Limited 100% · UK · Holding company
   5. MRX Medical Limited 100% · UK · Development & distribution of health products
   6. Aristaeus Elements Ltd 100% · UK · Manufacture of other organic basic chemicals and essential oils
   7. Tiamat Australia PTY Ltd 100% · Australia · Wholesale of pharmaceutical goods

Significant events

• “MRX1 Technical Batch Completion (February 2025): The Company completed the manufacture of its final technical batch of MRX1 to support the Investigational Medicinal Product Dossier (IMPD), a regulatory requirement for MHRA clinical trial approval.”
• “Ethics and Regulatory Approvals: Ethics approval was granted by the Alfred Hospital Human Research Ethics Committee (HREC) in April 2025, followed by Clinical Trial Notification (CTN) acknowledgement by the Australian Therapeutic Goods Administration (TGA).”
• “MRX1 Stability Data Achievement (June 2025): MRX1 achieved 24-month stability data under both standard and accelerated conditions, in accordance with ICH guidelines. This further validates its pharmaceutical robustness and regulatory readiness.”
• “GMP Manufacturing Milestone (June 2025): Ananda manufactured forty litres each of MRX1 and matched placebo to Good Manufacturing Practice (GMP) standards. This represents the largest and first GMP-certified production of MRX1.”
• “Product Delivery to Clinical Trial Site (June 2025): Following GMP manufacture, MRX1 was successfully delivered to the clinical site in Australia, confirming supply chain readiness.”
• “Initiation of Phase 1 PK Study (July 2025): The first participant was dosed in Ananda's Phase 1 pharmacokinetic (PK) study of MRX1 in Melbourne, Australia, with initial results expected in Q1 2026.”
• “Appointment of High-Profile Industry Advisors: In April and May 2025. Ananda appointed two former GW Pharmaceuticals executives: Chris Tovey, former COO of GW and Jazz Pharmaceuticals. Giles Moss, former GM of Europe at GW.”
• “Commercial Expertise Expansion (February 2025): Andy Rust, former Global Head of Respiratory at Chiesi Group, joined as commercial advisor.”
• “Engagement of U.S. Strategic Advisors (January 2025): Ananda appointed Viridian Capital Advisors, a New York-based cannabis industry advisory firm.”
• “OTCQB Admission (April 2025): Ananda's shares began trading on the U.S. OTCQB Venture Market under the ticker "ANANF".”
• “Benzinga Cannabis Capital Conference (June 2025): Ananda's senior leadership attended the Benzinga Conference in Chicago.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

10

last 12 months

Capital events

4

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  +1,871%

  £84,431 → £1,664,098

• Net assets

  +505.6%

  £351,344 → £2,127,600

• Employees

  -25%

  12 → 9

• Operating profit

  +45.6%

  -£6,932,067 → -£3,770,487

• Profit before tax

  +45.6%

  -£6,932,067 → -£3,770,487

• Wages

  -26.1%

  £682,801 → £504,623

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers